The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint
microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size, specific targetability, and critical role in disease pathogenesis. However, <20 miR targeting molecules have entered clinical trials, and none progressed to phase III. The difficulties in miR target ident...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8d2384e466034a058851f9185a462798 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8d2384e466034a058851f9185a462798 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8d2384e466034a058851f9185a4627982021-11-25T17:11:28ZThe Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint10.3390/cells101130972073-4409https://doaj.org/article/8d2384e466034a058851f9185a4627982021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3097https://doaj.org/toc/2073-4409microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size, specific targetability, and critical role in disease pathogenesis. However, <20 miR targeting molecules have entered clinical trials, and none progressed to phase III. The difficulties in miR target identification, the moderate efficacy of miR inhibitors, cell type-specific delivery, and adverse outcomes have impeded the development of miR therapeutics. These hurdles are rooted in the functional complexity of miR’s role in disease and sequence complementarity-dependent/-independent effects in nontarget tissues. The advances in understanding miR’s role in disease, the development of efficient miR inhibitors, and innovative delivery approaches have helped resolve some of these hurdles. In this review, we provide a multidisciplinary viewpoint on the challenges and opportunities in the development of miR therapeutics.Mohammad Yahya MominRavinder Reddy GaddamMadeline KravitzAnisha GuptaAjit VikramMDPI AGarticlepeptide nucleic acidsmiR deliverymiRNAplant-derived miRsBiology (General)QH301-705.5ENCells, Vol 10, Iss 3097, p 3097 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
peptide nucleic acids miR delivery miRNA plant-derived miRs Biology (General) QH301-705.5 |
| spellingShingle |
peptide nucleic acids miR delivery miRNA plant-derived miRs Biology (General) QH301-705.5 Mohammad Yahya Momin Ravinder Reddy Gaddam Madeline Kravitz Anisha Gupta Ajit Vikram The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint |
| description |
microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size, specific targetability, and critical role in disease pathogenesis. However, <20 miR targeting molecules have entered clinical trials, and none progressed to phase III. The difficulties in miR target identification, the moderate efficacy of miR inhibitors, cell type-specific delivery, and adverse outcomes have impeded the development of miR therapeutics. These hurdles are rooted in the functional complexity of miR’s role in disease and sequence complementarity-dependent/-independent effects in nontarget tissues. The advances in understanding miR’s role in disease, the development of efficient miR inhibitors, and innovative delivery approaches have helped resolve some of these hurdles. In this review, we provide a multidisciplinary viewpoint on the challenges and opportunities in the development of miR therapeutics. |
| format |
article |
| author |
Mohammad Yahya Momin Ravinder Reddy Gaddam Madeline Kravitz Anisha Gupta Ajit Vikram |
| author_facet |
Mohammad Yahya Momin Ravinder Reddy Gaddam Madeline Kravitz Anisha Gupta Ajit Vikram |
| author_sort |
Mohammad Yahya Momin |
| title |
The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint |
| title_short |
The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint |
| title_full |
The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint |
| title_fullStr |
The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint |
| title_full_unstemmed |
The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint |
| title_sort |
challenges and opportunities in the development of microrna therapeutics: a multidisciplinary viewpoint |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/8d2384e466034a058851f9185a462798 |
| work_keys_str_mv |
AT mohammadyahyamomin thechallengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT ravinderreddygaddam thechallengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT madelinekravitz thechallengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT anishagupta thechallengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT ajitvikram thechallengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT mohammadyahyamomin challengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT ravinderreddygaddam challengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT madelinekravitz challengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT anishagupta challengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint AT ajitvikram challengesandopportunitiesinthedevelopmentofmicrornatherapeuticsamultidisciplinaryviewpoint |
| _version_ |
1718412663363469312 |